Achieve Life Sciences, Inc. (QUIT) Stock Price & Fundamentals
Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence.
Valuation
Financials & Margins
Achieve Life Sciences, Inc. key facts
Strengths in the numbers
- Debt/equity 0.68, below the 1.09 median across 5 Medical - Pharmaceuticals peers (largest by market cap).
Points to check
- Net income was negative in each of the last 5 fiscal years (2021–2025).
- Cash from operations was negative in each of the last 5 fiscal years.
- Free cash flow was negative in each of the last 5 fiscal years.
- Interest coverage -255.5×: operating profit did not cover interest expense in the latest year.
Computed by rule from the reported figures on this page. A description of the numbers, not advice.
Peer Comparison
Quarterly Results — Last 8 Quarters (USD millions)
Annual Financials (USD)
QUIT fundamentals by fiscal year
Pick a measure to chart 10 fiscal years (2016–2025) from the company’s annual statements. Only 1 fiscal year of operating margin on file — too few to chart. Only 1 fiscal year of net margin on file — too few to chart.
Total revenue reported for each fiscal year.
Show the numbers
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Net income (profit after all costs, interest and tax) for each fiscal year; a bar below the zero line is a net loss.
Show the numbers
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income | −$20M | −$11M | −$13M | −$16M | −$15M | −$33M | −$42M | −$30M | −$40M | −$55M |
Net income as a percentage of shareholders’ equity, by fiscal year.
Show the numbers
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | −105.3% | −137.5% | −81.3% | −88.9% | −40.5% | −117.9% | −525.0% | — | −190.5% | −250.0% |
Operating cash flow less capital expenditure, by fiscal year; below zero means more cash went out than came in from operations.
Show the numbers
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | −$30M | −$9M | −$11M | −$15M | −$13M | −$29M | −$38M | −$24M | −$30M | −$49M |
Earnings per share for each fiscal year.
Show the numbers
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS | −$1474.98 | −$441.47 | −$72.29 | −$39.15 | −$5.39 | −$4.05 | −$3.95 | −$1.50 | −$1.24 | −$1.25 |
Balance Sheet (USD)
Cash Flow (USD)
Efficiency Ratios (fiscal years)
ROCE is profit before interest and tax divided by total assets less current liabilities. Payable days and the cash conversion cycle need a trade-payables line, which these statements do not carry.
Valuation & Return Ratios
Ownership
For Achieve Life Sciences, Inc., insiders hold 0.91% of the shares, institutions hold 83.80%, according to the latest holder filings.
Filings & documents
Achieve Life Sciences, Inc. (QUIT) reports filed with the US Securities and Exchange Commission, newest first. SEC CIK 0000949858. Links open sec.gov.
Annual reports (10-K)
Latest: 10-K for fiscal 2025 (period ended 31 Dec 2025), filed 24 Mar 2026. Document · Filing index
2 amended annual reports are listed on EDGAR.
Quarterly reports (10-Q)
Labelled by the quarter's period end.
Recent events (8-K)
- Results of operations8-KPress release (EX-99.1)
- Director/officer change8-K
- Other events8-K
- Results of operations8-KPress release (EX-99.1)
- Charter or bylaw amendment; Shareholder vote results8-K
Proxy statements (DEF 14A)
Source: SEC EDGAR, checked 16 Nov 2026. All filings on SEC EDGAR
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
Achieve Life Sciences, Inc. (QUIT) stock trades at $6.15 with a market capitalization of $632.35M. The stock is valued at a negative price-to-earnings (P/E) ratio of -5.12, reflecting a net loss over the last twelve months, price-to-book of 29.94, price-to-sales of 5776.95. Over the past 52 weeks the stock has ranged between $2.62 and $8.64, and currently trades 28.8% below its 52-week high.
On profitability, Achieve Life Sciences, Inc. generates a return on equity (ROE) of -250.00% (negative, reflecting a net loss), return on capital employed of -34.28%.
Official website: www.achievelifesciences.com
Achieve Life Sciences, Inc. by the numbers, 2016–2025
Between 2016 and 2025 Achieve Life Sciences, Inc. reported revenue of $5.0M falling to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. The net loss widened from −$20.0M in 2016 to −$55.0M in 2025.
On a trailing twelve-month basis to Sep '26, revenue is $0 and net profit −$112.0M.
Borrowings stand at $15.0M, cash on hand is $60.0M, cash from operations was −$49.0M in the latest year, positive in 0 of the last 10.
Return on equity has averaged 383.3% over five years, and was -250.0% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Achieve Life Sciences, Inc. (QUIT) — frequently asked questions
What is Achieve Life Sciences, Inc. (QUIT) stock price today?
Achieve Life Sciences, Inc. (QUIT) is currently trading at $6.15, down 2.77% today.
What is QUIT P/E ratio?
Achieve Life Sciences, Inc.'s P/E ratio is -5.12. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is QUIT return on equity (ROE)?
Achieve Life Sciences, Inc.'s return on equity (ROE) is -250.00%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Achieve Life Sciences, Inc.'s market cap?
Achieve Life Sciences, Inc. has a market capitalization of $632.35M.
Does QUIT pay a dividend?
Achieve Life Sciences, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does QUIT carry?
Achieve Life Sciences, Inc. has a debt-to-equity ratio of 0.68. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What sector is QUIT in?
Achieve Life Sciences, Inc. is classified under Healthcare, in the Medical - Pharmaceuticals industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is QUIT listed on?
Achieve Life Sciences, Inc. trades on NASDAQ under the ticker QUIT.
What is QUIT's 52-week range?
Over the last year Achieve Life Sciences, Inc. has traded between $2.62 and $8.64.
Related Healthcare Stocks
Popular Stocks
Screens QUIT currently matches
On the figures above, Achieve Life Sciences, Inc. passes the filters for 6 of our ready-made screens, among them Small Cap Stocks, Stocks Under $10, Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.